1. Home
  2. SONO vs EYPT Comparison

SONO vs EYPT Comparison

Compare SONO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonos Inc.

SONO

Sonos Inc.

HOLD

Current Price

$15.34

Market Cap

1.8B

ML Signal

HOLD

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$12.25

Market Cap

1.5B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
SONO
EYPT
Founded
2002
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Laboratory Analytical Instruments
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
2018
2005

Fundamental Metrics

Financial Performance
Metric
SONO
EYPT
Price
$15.34
$12.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$19.67
$28.75
AVG Volume (30 Days)
1.5M
1.0M
Earning Date
02-03-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,438,081,000.00
$42,339,000.00
Revenue This Year
$3.93
N/A
Revenue Next Year
$8.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.63
$3.91
52 Week High
$19.82
$19.11

Technical Indicators

Market Signals
Indicator
SONO
EYPT
Relative Strength Index (RSI) 43.58 27.16
Support Level $14.12 $14.62
Resistance Level $15.14 $15.92
Average True Range (ATR) 0.72 1.08
MACD 0.02 -0.38
Stochastic Oscillator 36.57 3.73

Price Performance

Historical Comparison
SONO
EYPT

About SONO Sonos Inc.

Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: